NKARTA INC (NKTX:NASDAQ)
$2.91 0.1 (3.5587%)
Analysed NKARTA INC (NKTX:NASDAQ) News Sources
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
17-04-2026
yahoo.com
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
23-07-2026
yahoo.com
Nkarta to Participate in Needham Virtual Healthcare Conference
09-04-2026
yahoo.com
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
15-04-2026
yahoo.com
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
12-05-2026
yahoo.com
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
14-05-2026
yahoo.com
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
26-06-2026
yahoo.com
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
10-08-2026
yahoo.com
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
08-09-2026
yahoo.com
Nkarta to Participate in September Investor Conferences
10-09-2026
yahoo.com
What is the current price of NKARTA INC (NKTX:NASDAQ)?
The current price of NKARTA INC (NKTX:NASDAQ) is $2.91.
NKARTA INC (NKTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of NKARTA INC (NKTX:NASDAQ) since the previous trading day is $0.1.
NKARTA INC (NKTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of NKARTA INC (NKTX:NASDAQ) since the previous trading day is 3.5587%.
What is the most recent average sentiment score for NKARTA INC (NKTX:NASDAQ)?
The most recent average sentiment score for NKARTA INC (NKTX:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for NKARTA INC (NKTX:NASDAQ)?
The most recent sentiment for NKARTA INC (NKTX:NASDAQ) is .
SEC-8K** Filing Available For NKARTA INC (NKTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.